AEMD

Aethlon Medical, Inc. (AEMD) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the three-month period ended June 30, 2026. Aethlon Medical, Inc. is a clinical-stage medical therapeutic company developing the Hemopurifier® (HP), an investigational immunotherapeutic device designed to remove enveloped viruses and extracellular vesicles (EVs) from biological fluids. The company holds "Breakthrough Device" designation from the FDA for oncology and life-threatening viral indications. As of the filing date, the company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: The company reported no revenue for the period. Operating expenses included approximately $549,000 in Research and Development (R&D) costs.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by approximately $213,000 (11.9%) compared to the prior year period. This was driven primarily by a $142,000 decrease in professional fees (due to lower investor relations and accounting costs) and a $73,000 decrease in general and administrative expenses.
• Net Loss Improvement: Net loss decreased by approximately $214,000 year-over-year, reflecting the reduction in operating expenses.
• Share Count and EPS: The significant improvement in loss per share (from $(42.42) to $(4.02)) is largely attributable to a substantial increase in the weighted average number of shares outstanding (from 41,529 to 384,705) due to equity issuances and a retroactively applied 5-for-1 reverse stock split.
• Financing Activity: Unlike the prior year, the company generated significant cash from financing activities ($1.82 million) through its At-the-Market (ATM) offering program, issuing 160,028 shares for net proceeds of approximately $1.82 million.

Outlook, Management Commentary, and Risks

• Clinical Progress: The company is advancing its Phase 1 oncology clinical trial in Australia. Cohort 3 was initiated in the first fiscal quarter of 2027 (subsequent to the reporting period), and enrollment continues. The company discontinued a planned clinical trial in India to conserve resources.
• Liquidity: Management believes that cash on hand as of June 30, 2026, combined with proceeds from a registered public offering completed in July 2026 (generating ~$4.0 million gross), will fund operations for at least the next twelve months. However, additional capital will likely be required to advance clinical development beyond that period.
• Subsequent Events:
  • Public Offering: On July 7, 2026, the company completed a best-efforts public offering of common stock, pre-funded warrants, and warrants, generating gross proceeds of approximately $4.0 million.
  • Reverse Stock Split: A 5-for-1 reverse stock split was effected on July 31, 2026, with trading on a split-adjusted basis commencing August 4, 2026.
• Risks: Key risks include the inability to raise additional capital, delays in clinical trials, failure to obtain regulatory approval, and the uncertainty of market acceptance. The company has no current revenue and relies on financing to fund operations.

Investor Verification Checklist

• Verify the status and enrollment numbers of the Phase 1 oncology trial in Australia, specifically regarding Cohort 3.
• Confirm the utilization of proceeds from the July 2026 public offering and the ATM program to ensure the projected 12-month cash runway remains valid.
• Monitor the impact of the 5-for-1 reverse stock split on liquidity and trading volume on the Nasdaq Capital Market.
• Review the timeline for the expiration of the company's facility leases (March 2027) and potential renewal or relocation costs.
• Assess the progress of the Long COVID research manuscript and its potential to open new therapeutic indications.